Bristol Myers Squibb Canada Co., a subsidiary of the renowned global biopharmaceutical company Bristol Myers Squibb, is headquartered in Canada and operates extensively across the country. Founded in 1887, the company has established itself as a leader in the pharmaceutical industry, focusing on innovative medicines in areas such as oncology, immunology, and cardiovascular disease. Bristol Myers Squibb is known for its commitment to research and development, with core products that include groundbreaking therapies like Opdivo and Eliquis, which have transformed treatment paradigms. The company’s dedication to advancing science and improving patient outcomes has positioned it as a key player in the Canadian healthcare landscape. With a strong emphasis on collaboration and innovation, Bristol Myers Squibb continues to achieve notable milestones in the fight against serious diseases.
How does Bristol Myers Squibb Canada Co.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bristol Myers Squibb Canada Co.'s score of 52 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bristol Myers Squibb Canada Co. currently does not have available carbon emissions data for the most recent year, as no specific figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. In the absence of specific emissions data, it is important to note that many companies in the pharmaceutical industry are increasingly focusing on sustainability and climate commitments. This often includes setting science-based targets for reducing greenhouse gas emissions across various scopes, including Scope 1 (direct emissions), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions from the value chain). Bristol Myers Squibb Canada Co. may be engaging in similar efforts to align with industry standards and contribute to global climate goals, although specific commitments or targets have not been disclosed.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bristol Myers Squibb Canada Co. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.